| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Apr―24 |
Workplace Vaccination Against COVID-19 and Seasonal Influenza in the United States: A Modeling-Based Estimation of the Health and Economic Benefits for Employers and Employees |
Ekkehard Beck, Keya Joshi, Darshan Mehta, Stephane Lorenc, Bishoy Rizkalla, Nicolas Van de Velde |
| 2 |
[GO] |
2025―Feb―12 |
Healthcare Resource Utilization (HCRU) and Direct Medical Costs Associated with Long COVID or Post-COVID-19 Conditions: Findings from a Literature Review |
Elżbieta Łukomska, Krzysztof Kloc, Malwina Kowalska, Aleksandra Matjaszek, Keya Joshi, Stefan Scholz, et al. (+2) Nicolas Van de Velde, Ekkehard Beck |
| 3 |
[GO] |
2024―Dez―10 |
Operational Efficiency of Public Hospitals in Greece During the COVID-19 Pandemic: A Comparative Analysis Using DEA and AHP Models |
Athanasios Mitakos, Panagiotis Mpogiatzidis |
| 4 |
[GO] |
2024―Nov―12 |
Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach |
Matthew Sussman, Jennifer Benner, Tendai Mugwagwa, Jackie Lee, Sheng-Tzu Hung, Ya-Min Yang, Yixi Chen |
| 5 |
[GO] |
2024―Okt―29 |
Developer and Partnership Differences in COVID-19 and Other Infections: Insights from DNA Vaccines |
Ryo Okuyama |
| 6 |
[GO] |
2024―Okt―22 |
Adapting Efficiency Analysis in Health Systems: A Scoping Review of Data Envelopment Analysis Applications During the COVID-19 Pandemic |
Athanasios Mitakos, Panagiotis Mpogiatzidis |
| 7 |
[GO] |
2023―Jan―06 |
The burden of hospitalisations for COVID-19 in France: a study of all cases in the national insurance claims database in 2020 |
Claire Leboucher, Cécile Blein, Valérie Machuron, Kelly Benyounes, Katell Le lay, Aurélie Millier, et al. (+2) Romain Supiot, François Raffi |
| 8 |
[GO] |
2022―Aug―09 |
Impact of the COVID-19 pandemic on the conduct of clinical trials: a quantitative analysis |
Wojciech Margas, Piotr Wojciechowski, Mondher Toumi |
| 9 |
[GO] |
2022―Jun―10 |
Public health impact of COVID-19 in French ambulatory patients with at least one risk factor for severe disease |
Aurélie Millier, Romain Supiot, Kelly Benyounes, Valérie Machuron, Katell Le Lay, Marine Sivignon, et al. (+3) Claire Leboucher, Cécile Blein, François Raffi |
| 10 |
[GO] |
2021―Nov―11 |
On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe |
Katarzyna Jabłońska, Samuel Aballéa, Pascal Auquier, Mondher Toumi |
| 11 |
[GO] |
2020―Okt―08 |
Chinese guidelines related to novel coronavirus pneumonia |
Tingting Qiu, Shuyao Liang, Monique Dabbous, Yitong Wang, Ru Han, Mondher Toumi |
| 12 |
[GO] |
2020―Sep―11 |
A critical analysis and review of Lancet COVID-19 hydroxychloroquine study |
Mondher Toumi, Malgorzata Biernikiewicz, Shuyao Liang, Yitong Wang, Tingting Qiu, Ru Han |
| 13 |
[GO] |
2020―Mai―13 |
Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al |
Mondher Toumi, Samuel Aballea |
